Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

This study has been completed.

Sponsor:

Information provided by:

Kentuckiana Cancer Institute

ClinicalTrials.gov Identifier:

NCT00283478

First received: January 26, 2006

Last updated: October 30, 2007

Last verified: October 2007

History of Changes

Purpose

To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.

Condition	Intervention
Non-Small Cell Lung Cancer	Drug: Iscar Quercus Drug: Gemcitabine


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Randomized Pilot Study of Supplemental Iscar in Combination With Gemcitabine vs. Gemcitabine Alone as Second Line Treatment for Advanced Non-Small Cell Lung Cancer.

Resource links provided by NLM:

Genetics Home Reference related topics: lung cancer

MedlinePlus related topics: Cancer Lung Cancer

Drug Information available for: Gemcitabine Gemcitabine hydrochloride

U.S. FDA Resources

Further study details as provided by Kentuckiana Cancer Institute:

Primary Outcome Measures:

To determine if Iscar improves immune function and quality of life.


Estimated Enrollment:	20
Study Start Date:	May 2004
Study Completion Date:	April 2007

Detailed Description:

RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine alone as second line treatment for advanced non-small cell lung cancer.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo
Karnofsky score 60% or greater
patients who will be treated with Gemcitabine

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00283478

Locations


United States, Kentucky
Kentuckiana Cancer Institute
Louisville, Kentucky, United States, 40202

Sponsors and Collaborators

Kentuckiana Cancer Institute

Investigators


Study Director:	Renato V. LaRocca, MD	Kentuckiana Cancer Institute

More Information


ClinicalTrials.gov Identifier:	NCT00283478 History of Changes
Other Study ID Numbers:	1056757 Mistletoe
Study First Received:	January 26, 2006
Last Updated:	October 30, 2007
Health Authority:	United States: Food and Drug Administration

Keywords provided by Kentuckiana Cancer Institute:


Advanced stage Lung cancer

Additional relevant MeSH terms:


Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Gemcitabine	Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 23, 2016

To Top